Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial
Brian H. Kushner, Shakeel Modak, Audrey Mauguen, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung · 2025
Read Naxitamab plus stepped-up dosing of granulocyte–macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial by Brian H. Kushner, Shakeel Modak, Audrey Mauguen, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12752410.txt.
Description
BackgroundWith high-risk neuroblastoma, post-induction metastases in bone marrow (BM)/bones confers a poor prognosis but can respond to anti-GD2 antibody, such as naxitamab. We report results of a phase I/II trial.MethodsCycles included GM-CSF and naxitamab infused (30-to-90 min) on days + 1, + 3, + 5. Naxitamab was dose-escalated in the trial’s phase I portion and administered at 9 mg/kg/cycle (i.e.
Catalog record
| CREATOR | Brian H. Kushner, Shakeel Modak, Audrey Mauguen, Ellen M. Basu, Stephen S. Roberts, Nai-Kong V. Cheung |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |